Skip to main content
SpringerLink
Log in

BREVAGen: cost effective in directing tamoxifen therapy?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Green LE, et al. Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women with a Previous Breast Biopsy. Applied Health Economics and Health Policy : 5 Mar 2014. Available from: URL: http://dx.doi.org/10.1007/s40258-014-0089-6.

    PubMed  Google Scholar 

  2. Genetic Technologies. Genetic Technologies Announces Publication of Economic Modeling Study Supporting Cost-Effectiveness of BREVAGen(Tm) to Direct Tamoxifen Chemoprevention. Media Release : 7 Mar 2014. Available from: URL: http://www.gtglabs.com.

Download references

Additional information

* single nucleotide polymorphism

** funding provided by Perlegen Sciences, Inc. and Genetic Technologies, Ltd

Rights and permissions

Reprints and permissions

About this article

Cite this article

BREVAGen: cost effective in directing tamoxifen therapy?. PharmacoEcon Outcomes News 699, 4 (2014). https://doi.org/10.1007/s40274-014-1131-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1131-5

Search

Navigation